Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of C16TR in Healthy Volunteers
NCT06193031Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Nov 2015
- Primary completion
- Dec 2015
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of treprostinil palmitil in pulmonary arterial hypertension (PAH) (3 cohorts), sponsored by Insmed Incorporated. Primary endpoint: Number of Participants who Experienced an Adverse Event (AE) up to 32 days. Started Nov 2015; status: completed.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06193031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193031.